In the SAFE-PAD cohort study of patients with peripheral artery disease designed in part by the FDA, there was no difference in mortality between those treated with paclitaxel-coated devices and those treated with uncoated devices.The results of SAFE-PAD, a retrospective cohort study designed after feedback from the FDA, were presented by Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM,